Adaptate Biotherapeutics Ltd

2022 turned out to be a relatively quiet year on the M&A and partnering front in Japan – or at least it was until mid-December, when Takeda Pharmaceutical Co. Ltd. announced it would pay an eye-wate

2022 turned out to be a relatively quiet year on the M&A and partnering front in Japan – or at least it was until mid-December, when Takeda Pharmaceutical Co. Ltd. announced it would pay an eye-wate

Immunocore Closing In On First Ever TCR Immunotherapy Approval Immunocore could be just weeks away from gaining US approval for its immunotherapy, tebentafusp (IMCgp100), which would make it the fir

Immunocore Closing In On First Ever TCR Immunotherapy Approval Immunocore could be just weeks away from gaining US approval for its immunotherapy, tebentafusp (IMCgp100), which would make it the fir